Formulation of acyclovir-loaded solid lipid nanoparticles: 2. Brain targeting and pharmacokinetic study

References

• Araujo L, Sheppard M, Lobenberg R, Kreuter J. 1999. Uptake of PMMA nanoparticles from the gastrointestinal tract after oral administration to rats: modification of the body distribution after solution in surfactant solutions and in oil vehicles. Int J Pharm. 176(2):209–224.
   Google Scholar
• Attia IA, El-Gizawy SA, Fouda MA, Donia AM. 2007. Influence of a niosomal formulation on the oral bioavailability of acyclovir in rabbits. AAPS PharmSciTech. 8(4):206.
   Web of Science ®Google Scholar
• Blasi P, Giovagnoli S, Schoubben A, Ricci M, Rossi C. 2007. Solid lipid nanoparticles for targeted brain drug delivery. Adv Drug Deliv Rev. 59(6):454–477.
   PubMed Web of Science ®Google Scholar
• Chacko BJ, Palanisamy S, Gowrishankar NL, Honeypriya J, Sumathy A. 2018. Effect of surfactant coating on brain targeting polymeric nanoparticles; a review. Indian J Pharm Sci. 80(2):215–222.
   Web of Science ®Google Scholar
• Chattopadhyay N. 2007. Development of solid lipid nanoparticles (SLNs) for enhanced delivery of the protease inhibitor (PI), atazanavir, to human brain endothelial cells [master’s thesis]. Canada (Ontario): University of Toronto.
   Google Scholar
• Garré B, Shebany K, Gryspeerdt A, Baert K, van der Meulen K, Nauwynck H, Deprez P, De Backer P, Croubels S. 2007. Pharmacokinetics of acyclovir after intravenous infusion of acyclovir and after oral administration of acyclovir and its prodrug valacyclovir in healthy adult horses. Antimicrob Agents Chemother. 51(12):4308–4314.
   PubMed Web of Science ®Google Scholar
• Gasco MR, Antonelli LP. 1993. Method for preparing solid lipid microspheres having a narrow size distribution. United States patent US 5,250,236.
   Google Scholar
• Gupta S, Kesarla R, Chotai N, Misra A, Omri A. 2017. Systematic approach for the formulation and optimization of solid lipid nanoparticles of efavirenz by high pressure homogenization using design of experiments for brain targeting and enhanced bioavailability. Biomed Res Int. 2017:5984014.
   PubMed Web of Science ®Google Scholar
• Hassan H, Adam SK, Othman F, Shamsuddin AF, Basir R. 2016. Antiviral nanodelivery systems: current trends in acyclovir administration. J Nanomater. 2016.
   Google Scholar
• Jain N, Jain R, Thakur N, Gupta BP, Jain DK, Banveer J, Jain S. 2010. Nanotechnology: a safe and effective drug delivery system. Asian J Pharm Clin Res. 3(3):159–165.
   Google Scholar
• Jianping Qi, Yi Lu, Wei Wu. 2012. Absorption, disposition and pharmacokinetics of solid lipid nanoparticles. Curr Drug Metab. 13(4):418–428.
   PubMed Web of Science ®Google Scholar
• Joshi SA, Chavhan SS, Sawant KK. 2010. Rivastigmine-loaded PLGA and PBCA nanoparticles: preparation, optimization, characterization, in vitro and pharmacodynamic studies. Eur J Pharm Biopharm. 76(2):189–199.
   PubMed Web of Science ®Google Scholar
• Kadam RS, Bourne DWA, Kompella UB. 2012. Nano-advantage in enhanced drug delivery with biodegradable nanoparticles: contribution of reduced clearance. Drug Metab Dispos. 40(7):1380–1388.
   PubMed Web of Science ®Google Scholar
• Kamel AO, Awad GAS, Geneidi AS, Mortada ND. 2009. Preparation of intravenous stealthy acyclovir nanoparticles with increased mean residence time. AAPS PharmSciTech. 10(4):1427–1436.
   PubMed Web of Science ®Google Scholar
• Kim JH, Lee MK, Kim JE, Kim SH, Choi SS. 2016. Comparison of intrathecal concentrations of acyclovir following epidural and intravenous administration in rats. Pain Physician. 19(4):E613–E619.
   PubMed Web of Science ®Google Scholar
• Klement W, Arndt JO. 1991. Pain on i.v. injection of some anaesthetic agents is evoked by the unphysiological osmolality or pH of their formulations. Br J Anaesth. 66(2):189–195.
   PubMed Web of Science ®Google Scholar
• Koziara JM, Lockman PR, Allen DD, Mumper RJ. 2003. In situ blood-brain barrier transport of nanoparticles. Pharm Res. 20(11):1772–1778.
   PubMed Web of Science ®Google Scholar
• Kreuter J. 2004. Influence of the surface properties on nanoparticle-mediated transport of drugs to the brain. J Nanosci Nanotechnol. 4(5):484–488.
   PubMed Web of Science ®Google Scholar
• Laskin OL. 1983. Clinical pharmacokinetics of acyclovir. Clin Pharmacokinet. 8(3):187–201.
   PubMed Web of Science ®Google Scholar
• Lee YC, Zocharski PD, Samas B. 2003. An intravenous formulation decision tree for discovery compound formulation development. Int J Pharm. 253(1–2):111–119.
   PubMedGoogle Scholar
• Lu W. 2012. Adsorptive-mediated brain delivery systems. Curr Pharm Biotechnol. 13(12):2340–2348.
   PubMed Web of Science ®Google Scholar
• Matsumoto K, Kurihara Y, Kuroda Y, Hori S, Kizu J. 2016. Pharmacokinetics and brain penetration of carbapenems in mice. J Infect Chemother. 22(5):346–349.
   PubMed Web of Science ®Google Scholar
• Mittal D, Md S, Hasan Q, Fazil M, Ali A, Baboota S, Ali J. 2016. Brain targeted nanoparticulate drug delivery system of rasagiline via intranasal route. Drug Deliv. 23(1):130–139.
   PubMed Web of Science ®Google Scholar
• Muller RH, Maassm S, Weyhers H, Mehnert W. 1996. Phagocytic uptake and cytotoxicity of solid lipid nanoparticles (SLN) stoically stabilized with Poloxamine 908 and Poloxamer 407. J Drug Target. 4:161–170.
   PubMed Web of Science ®Google Scholar
• Muller RH, Ruhl B, Runge S, Schulze-Foster K, Mehnert W. 1997. Cytotoxicity of solid lipid nanoparticles as a function of the lipid matrix and the surfactant. Pharm Res. 14:458–462.
   PubMed Web of Science ®Google Scholar
• Neves AR, Queiroz JF, Reis S. 2016. Brain‑targeted delivery of resveratrol using solid lipid nanoparticles functionalized with apolipoprotein E. J Nanobiotechnol. 14(1):27.
   PubMedGoogle Scholar
• Olbrich C, Kayser O, Müller RH. 2002. Lipase degradation of Dynasan 114 and 116 solid lipid nanoparticles (SLN)—Effect of surfactants, storage time and crystallinity. Int J Pharm. 237(1–2):119–128.
   PubMed Web of Science ®Google Scholar
• Patel PJ, Gohel MC, Acharya SR. 2014. Exploration of statistical experimental design to improve entrapment efficiency of acyclovir in poly (d, l) lactide nanoparticles. Pharm Dev Technol. 19(2):200–212.
   PubMed Web of Science ®Google Scholar
• Pivette P, Faivre V, Brubach J-B, Daste G, Ollivon M, Lesieur S. 2014. Polymorphism of glyceryl behenates: from the individual compounds to the pharmaceutical excipient. Chem Phys Lipids. 183:191–203.
   PubMed Web of Science ®Google Scholar
• Prabhakar K, Afzal SM, Surender G, Kishan V. 2013. Tween 80 containing lipid nanoemulsions for delivery of indinavir to brain. Acta Pharm Sin B. 3(5):345–353.
   Web of Science ®Google Scholar
• Qin Y, Fan W, Chen H, Yao N, Tang W, Tang J, Yuan W, Kuai R, Zhang Z, Wu Y. 2010. In vitro and in vivo investigation of glucose-mediated brain-targeting liposomes. J Drug Target. 18(7):536–549.
   PubMed Web of Science ®Google Scholar
• Quenelle DC, Birkmann A, Goldner T, Pfaff T, Zimmermann H, Bonsmann S, Collins DJ, Rice TL, Prichard MN. 2018. Efficacy of pritelivir and acyclovir in the treatment of herpes simplex virus infections in a mouse model of herpes simplex encephalitis. Antiviral Res. 149:1–6.
   PubMed Web of Science ®Google Scholar
• Seyfoddin A, Al-Kassas R. 2013. Development of solid lipid nanoparticles and nanostructured lipid carriers for improving ocular delivery of acyclovir. Drug Dev Ind Pharm. 39(4):508–519.
   PubMed Web of Science ®Google Scholar
• Shi F, Zhao J-H, Liu Y, Wang Z, Zhang Y-T, Feng N-P. 2012. Preparation and characterization of solid lipid nanoparticles loaded with frankincense and myrrh oil. Int J Nanomedicine. 7:2033–2043.
   PubMed Web of Science ®Google Scholar
• Smith JP, Weller S, Johnson B, Nicotera J, Luther JM, Haas DW. 2010. Pharmacokinetics of acyclovir and its metabolites in cerebrospinal fluid and systemic circulation after administration of high-dose valacyclovir in subjects with normal and impaired renal function. Antimicrob Agents Chemother. 54(3):1146–1151.
   PubMed Web of Science ®Google Scholar
• Su J, Miao Q, Miao P, Zhao Y, Zhang Y, Chen N, Zhang Y, Ma S. 2015. Pharmacokinetics and brain distribution and metabolite identification of coptisine, a protoberberine alkaloid with therapeutic potential for CNS disorders, in rats. Biol Pharm Bull. 38(10):1518–1528.
   PubMed Web of Science ®Google Scholar
• Sun W, Xie C, Wang H, Hu Y. 2004. Specific role of polysorbate 80 coating on the targeting of nanoparticles to the brain. Biomaterials. 25(15):3065–3071.
   PubMed Web of Science ®Google Scholar
• Thakkar A, Chenreddy S, Thio A, Khamas W, Wang J, Prabhu S. 2016. Preclinical systemic toxicity evaluation of chitosan-solid lipid nanoparticle-encapsulated aspirin and curcumin in combination with free sulforaphane in BALB/c mice. Int J Nanomedicine. 11:3265–3276.
   PubMed Web of Science ®Google Scholar
• Trapani A, Denora N, Iacobellis G, Sitterberg J, Bakowsky U, Kissel T. 2011. Methotrexate-loaded chitosan- and glycol chitosan-based nanoparticles: a promising strategy for the administration of the anticancer drug to brain tumors. AAPS PharmSciTech. 12(4):1302–1311.
   PubMed Web of Science ®Google Scholar
• van Rooy I, Cakir-Tascioglu S, Hennink WE, Storm G, Schiffelers RM, Mastrobattista E. 2011. In vivo methods to study uptake of nanoparticles into the brain. Pharm Res. 28(3):456–471.
   PubMed Web of Science ®Google Scholar
• Velivela S, Abbulu K, Mayasa V, Pati NB. 2016. Method development and validation of acyclovir in rabbit plasma by RP-HPLC. J Pharm Res. 10(7):509–513.
   Google Scholar
• Vinay KV. 2010. Effect of surface modification of solid lipid nanoparticles in brain targeting [dissertation]. India (New Delhi): Jamia Hamdard University.
   Google Scholar
• Xu Z, Chen L, Gu W, Gao Y, Lin L, Zhang Z, Xi Y, Li Y. 2009. The performance of docetaxel-loaded solid lipid nanoparticles targeted to hepatocellular carcinoma. Biomaterials. 30(2):226–232.
   PubMed Web of Science ®Google Scholar
• Zeng L, Nath CE, Blair EYL, Shaw PJ, Stephen K, Earl JW, Coakley JC, McLachlan AJ. 2009. Population pharmacokinetics of acyclovir in children and young people with malignancy after administration of intravenous acyclovir or oral valacyclovir. Antimicrob Agents Chemother. 53(7):2918–2927.
   PubMed Web of Science ®Google Scholar